146 related articles for article (PubMed ID: 35787739)
1. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
[TBL] [Abstract][Full Text] [Related]
2. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
[TBL] [Abstract][Full Text] [Related]
5. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
6. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
[TBL] [Abstract][Full Text] [Related]
7. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation.
Gupta G; Gupta R; Pasricha S; Sharma A; Durga G; Kamboj M; Tripathi R; Mehta A
Indian J Pathol Microbiol; 2022; 65(4):832-838. PubMed ID: 36308189
[TBL] [Abstract][Full Text] [Related]
8. Stromal marker fibroblast activation protein drives outcome in T1 non-muscle invasive bladder cancer.
Muilwijk T; Akand M; Daelemans S; Marien K; Waumans Y; Kockx M; Baekelandt L; Van den Broeck T; Van der Aa F; Gevaert T; Joniau S
PLoS One; 2021; 16(9):e0257195. PubMed ID: 34525114
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
10. Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
Al-Sharaky DR; Abdelwahed M; Asaad N; Foda A; Abdou AG
J Immunoassay Immunochem; 2021 May; 42(3):236-251. PubMed ID: 33213275
[TBL] [Abstract][Full Text] [Related]
11. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
12. Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics.
Abd El-Azeem MA; Ali MA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2022 Sep; 34(1):40. PubMed ID: 36155866
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
15. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.
Shigeta K; Matsumoto K; Tanaka N; Mikami S; Kosaka T; Yasumizu Y; Takeda T; Mizuno R; Kikuchi E; Oya M
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563543
[TBL] [Abstract][Full Text] [Related]
16. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
[TBL] [Abstract][Full Text] [Related]
17. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
[TBL] [Abstract][Full Text] [Related]
19. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional Analysis of Immunohistochemically Defined Subgroups of Non-Muscle-Invasive Papillary High-Grade Upper Tract Urothelial Carcinoma.
Jung M; Lee JH; Kim B; Park JH; Moon KC
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
